Investing in Aurinia Pharmaceuticals Inc (AUPH)  ➔  Intrinsic value

Prev. close$23.24 
ModelValueUpside
Chepakovich$0.00-100%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$23.24  
Valuation MethodValuePotential 
Chepakovich Model$0.00-100%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Latest news

Company description

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.